GSK Discovers GSK’227 for Relapsed or Refractory Osteosarcoma
GSK has developed GSK’227 (GSK5764227) for the treatment of adult patients with relapsed or refractory osteosarcoma who have progressed after at least two prior lines of therapy.
GSK’227 is a first-in-class B7-H3-targeted antibody-drug conjugate (ADC) designed to address the urgent unmet needs of osteosarcoma patients. B7-H3, a surface antigen expressed in multiple solid tumors, serves as the target for this therapy.
Clinical trials have shown promising activity, particularly in relapsed or refractory cases. Data from the ARTEMIS-002 study, a phase II clinical trial, demonstrated significant efficacy and a manageable safety profile. Results from this trial were presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting.
Osteosarcoma is a rare but aggressive bone cancer, most commonly affecting children and young adults. For patients with relapsed or refractory disease, treatment options remain severely limited, with no approved therapies in later lines of care.
The ADC integrates a monoclonal antibody with a topoisomerase inhibitor payload, delivering potent antitumor effects.
With Breakthrough Therapy Designation granted by the U.S. FDA, GSK’227 marks a significant step toward providing new hope for patients battling this challenging disease.
